CR20180256A - Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico - Google Patents

Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico

Info

Publication number
CR20180256A
CR20180256A CR20180256A CR20180256A CR20180256A CR 20180256 A CR20180256 A CR 20180256A CR 20180256 A CR20180256 A CR 20180256A CR 20180256 A CR20180256 A CR 20180256A CR 20180256 A CR20180256 A CR 20180256A
Authority
CR
Costa Rica
Prior art keywords
preparation
compounds
therapeutic use
cryptoficine
new
Prior art date
Application number
CR20180256A
Other languages
English (en)
Spanish (es)
Inventor
Jidong; Zhang
Hervé; Bouchard
Marie-Priscille; Brun
Antony Bigot
François; Clerc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20180256A publication Critical patent/CR20180256A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bedding Items (AREA)
CR20180256A 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico CR20180256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
CR20180256A true CR20180256A (es) 2018-08-13

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180256A CR20180256A (es) 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico

Country Status (35)

Country Link
US (2) US10941139B2 (https=)
EP (1) EP3371179B1 (https=)
JP (1) JP6929292B2 (https=)
KR (1) KR102822076B1 (https=)
CN (1) CN108349960B (https=)
AR (1) AR106604A1 (https=)
AU (1) AU2016347724B2 (https=)
CA (1) CA3003085A1 (https=)
CL (1) CL2018001210A1 (https=)
CO (1) CO2018004581A2 (https=)
CR (1) CR20180256A (https=)
CY (1) CY1122441T1 (https=)
DK (1) DK3371179T3 (https=)
EA (1) EA035625B1 (https=)
EC (1) ECSP18034035A (https=)
ES (1) ES2755101T3 (https=)
HK (1) HK1256754B (https=)
HR (1) HRP20191729T1 (https=)
HU (1) HUE046033T2 (https=)
IL (1) IL259067B (https=)
LT (1) LT3371179T (https=)
MA (1) MA43160B1 (https=)
MX (1) MX374535B (https=)
MY (1) MY189448A (https=)
PH (1) PH12018500852B1 (https=)
PL (1) PL3371179T3 (https=)
PT (1) PT3371179T (https=)
RS (1) RS59498B1 (https=)
SG (1) SG11201803181SA (https=)
SI (1) SI3371179T1 (https=)
TN (1) TN2018000131A1 (https=)
TW (1) TWI714661B (https=)
UY (1) UY36979A (https=)
WO (1) WO2017076998A1 (https=)
ZA (1) ZA201802322B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
TN2019000303A1 (en) * 2017-05-10 2021-05-07 Sanofi Sa Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
EP4495105A1 (en) 2023-07-17 2025-01-22 Basf Se 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents
EP4495108A1 (en) 2023-07-17 2025-01-22 Basf Se 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510436A (ja) * 1993-12-21 1997-10-21 ユニバーシティー オブ ハワイ 新規なクリプトフィシン類
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
HUE046033T2 (hu) 2020-01-28
AU2016347724B2 (en) 2021-04-01
CL2018001210A1 (es) 2018-08-17
EP3371179B1 (en) 2019-08-07
HRP20191729T1 (hr) 2019-12-13
CO2018004581A2 (es) 2018-07-19
NZ741734A (en) 2023-10-27
JP6929292B2 (ja) 2021-09-01
LT3371179T (lt) 2019-11-11
US20210163458A1 (en) 2021-06-03
CN108349960B (zh) 2022-05-27
MX374535B (es) 2025-03-06
BR112018008490A2 (pt) 2019-02-12
WO2017076998A1 (en) 2017-05-11
KR102822076B1 (ko) 2025-06-18
TW201730164A (zh) 2017-09-01
PT3371179T (pt) 2019-11-18
JP2018535255A (ja) 2018-11-29
IL259067A (en) 2018-06-28
DK3371179T3 (da) 2019-11-11
ECSP18034035A (es) 2018-05-31
AU2016347724A1 (en) 2018-05-10
SI3371179T1 (sl) 2019-11-29
US20190382391A1 (en) 2019-12-19
TN2018000131A1 (en) 2019-10-04
MA43160B1 (fr) 2019-12-31
CY1122441T1 (el) 2021-01-27
PH12018500852A1 (en) 2018-10-29
EA035625B1 (ru) 2020-07-17
IL259067B (en) 2021-07-29
MX2018005379A (es) 2018-09-05
CN108349960A (zh) 2018-07-31
EA201890898A1 (ru) 2018-10-31
US10941139B2 (en) 2021-03-09
TWI714661B (zh) 2021-01-01
RS59498B1 (sr) 2019-12-31
ES2755101T3 (es) 2020-04-21
ZA201802322B (en) 2019-01-30
CA3003085A1 (en) 2017-05-11
KR20180073678A (ko) 2018-07-02
EP3371179A1 (en) 2018-09-12
UY36979A (es) 2017-06-30
AR106604A1 (es) 2018-01-31
HK1256754B (en) 2020-06-05
PL3371179T3 (pl) 2020-02-28
SG11201803181SA (en) 2018-05-30
MY189448A (en) 2022-02-14
PH12018500852B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
PY1909256A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35467A (es) Compuestos orgánicos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2017007377A (es) Compuestos organicos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
UY31871A (es) Compuestos que comprenden un grupo ciclobutoxi
UY37348A (es) Agentes antibacterianos de 2-pirrolidin fenilhidrazidas
UY38217A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
PY1735113A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos